Clinical Trial Update: Natalizumab in Recurrent, Refractory or Progressive Pulmonary Metastatic Osteosarcoma [Phase 1, Phase 2]

View source ↗

Summary

The Phase 1/Phase 2 trial of natalizumab for pulmonary metastatic osteosarcoma has been withdrawn.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Osteosarcoma

Drugs mentioned

• Tysabri (Natalizumab)

Snippet

Sponsor: Case Comprehensive Cancer Center | Conditions: Pulmonary Metastatic Osteosarcoma (pOS) | Phase 1, Phase 2 | Status: WITHDRAWN